Corgenix To Exhibit AspirinWorks Test At Denver Diabetes Expo
Recent clinical research1 has noted an increased prevalence of aspirin resistance among diabetic patients (Type II). During treatment with 81 mg aspirin, urinary levels of 11-dehydro thromboxane B2 levels were significantly higher in diabetic patients than non-diabetics. A significant reduction in resistance rates were noted with 325 mg of aspirin treatment as compared to 81mg.
"We know that not all individuals respond the same to the same dose of aspirin, and aspirin resistance is a concern of anyone taking aspirin to prevent heart attack and stroke," said Corgenix' Clinical Affairs Director Gordon Ens. "This is a great opportunity for the diabetic community and related medical professionals to learn more about the issue of aspirin resistance and how it may potentially impact management of type II diabetes."
AspirinWorks is a simple urine test that determines the effect of aspirin on platelets by measuring the level of thromboxane production (aspirin's target). The higher the levels of thromboxane, the stickier the blood platelets, and the less impact the aspirin is having. This crucial information allows physicians to individualize a patient's therapy.
The AspirinWorks Test, which was launched in the United States in June 2007 following FDA 510(k) clearance, is now available nationwide through major medical reference laboratories as well as direct to consumers through HealthCheckUSA (http://www.HealthCheckUSA.com).
Unlike other platelet tests, which require freshly drawn blood that must be evaluated within at least 4 hours, the AspirinWorks test only requires a urine sample that can be obtained in any doctor's office or patient service center, making the test easy for both physician and patient.
More information is also available at http://www.aspirinworks.com.
The Denver Diabetes Expo event features free screenings and exercise demos, guest celebrities, interactive educational sessions, a diabetes bookstore, El Mercadito Latino/Latin Marketplace, and exhibits featuring the latest products and services for diabetes awareness and management.
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network. More information is available at http://www.corgenix.com.
Statements in this press release that are not strictly historical facts are "forward-looking" statements (identified by the words "believe," "estimate," "project," "expect" or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company's products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company's periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.
1 Gurbel PA, et al "Effects of Diabetes on the Prevalence of Aspirin Resistance During Low Dose Aspirin Therapy" ACC meeting 2007; Abstract 1019-179.
Corgenix Medical Corporation
Corgenix de a expune AspirinWorks test de la Denver Expo diabet - Corgenix To Exhibit AspirinWorks Test At Denver Diabetes Expo - articole medicale engleza - startsanatate